Structural features of mammalian histidine decarboxylase reveal the basis for specific inhibition

British Journal of Pharmacology

Volumn 157, Issue 1, 2009, Pages 4-13

  Moya Garcia A A ^a,b   Pino Angeles A ^a,b   Gil Redondo, R ^c   Morreale, A ^c   Sanchez Jimenez F ^a,b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Histamine; Histidine decarboxylase; Homology modelling; Molecular dynamics; QM MM; Virtual screening

Indexed keywords

HISTIDINE DECARBOXYLASE; ENZYME INHIBITOR; LIGAND;

COMPUTER MODEL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIMULATION; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; PHYSIOLOGY; THERMODYNAMICS;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; ENZYME INHIBITORS; HISTIDINE DECARBOXYLASE; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 67149098340     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00219.x     Document Type: Review

References (94)

1. Abola E, Kuhn P, Earnest T, Stevens RC (2000). Automation of X-ray crystallography. Nat Struct Biol 7 (Suppl.): 973-977.
2. Ai W, Zheng H, Yang X, Liu Y, Wang TC (2007). Tip60 functions as a potential corepressor of KLF4 in regulation of HDC promoter activity. Nucleic Acids Res 35: 6137-6149. (Pubitemid 350018576)
3. Bajorath J (2001). Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening. J Chem InfComput Sci 41: 233-245. (Pubitemid 33717130)
4. Baker D, Sali A (2001). Protein structure prediction and structural genomics. Science 294: 93-96. (Pubitemid 32952955)
5. Berman H, Henrick K, Nakamura H, Markley JL (2007). The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res 35 (Database issue): D301-D303. (Pubitemid 46056219)
6. Bertoldi M, Gonsalvi M, Voltattomi CB (2001). Green tea polyphenols: novel irreversible Inhibitors of dopa decarboxylase. Biochem Biophys Res Commun 284: 90-93. (Pubitemid 32924313)
7. Bhattacharjee MK, Snell EE (1990). Pyridoxal S'-phosphate-dependent histidine decarboxylase. Mechanism of inactivation by alphafluoromethylhistidine. J Biol Chem 265: 6664-6668. (Pubitemid 20144543)
8. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A (2007). UniProtKB/Swiss-Prot: the manually annotated section of the UniProt KnowledgeBase. Methods MoI Biol 406: 89-112.
9. Brooks BR, Bruccoleri RE, Olafson DJ, States DJ, Swaminathan S, Karplus M (1983). CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4: 187-217.
10. Carlsson J, Aqvist J (2005). Absolute and relative entropies from computer simulation with applications to ligand binding. J Phys Chem 109: 6448-6456. (Pubitemid 40496862)
11. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE et al. (2004). AMBER 8. University of California: San Francisco.
12. Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, Merz KM Jr etal. (2005). The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
13. Chandonia JM, Brenner SE (2006). The impact of structural genomics: expectations and outcomes. Science 311: 347-351. (Pubitemid 43132652)
14. Chen D, Aihara T, Zhao CM, Hakanson R, Okabe S (2006). Differentiation of the gastric mucosa. I. Role of histamine in control of function and integrity of oxyntic mucosa: understanding gastric physiology through disruption of targeted genes. Am J Physiol Gastrointest Liver Physiol 291: G539-G544. (Pubitemid 44511671)
15. Chothia C, Lesk AM (1986). The relation between the divergence of sequence and structure in proteins. EMBO J 5: 823-826.
16. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, Emerson A etal. (2008). Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 51: 6237-6255.
17. Davis AM, Teague SJ, Kleywegt GJ (2003). Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem IntEdEngl 42: 2718-2736.
18. DeGraw JI, Engstrom J, Ellis M, Johnson HL (1977). Potential histidine decarboxylase inhibitors. 1. α- and β-Substituted histidine analogs. J Med Chem. 20: 1671-1674. (Pubitemid 8231448)
19. DeLano WL (2002). The PyMOL Molecular Graphics System. DeLano Scientific: San Carlos, CA.
20. Engel N, Olmo MT, Coleman CS, Medina MA, Pegg AE, Sanchez-Jimenez F (1996). Experimental evidence for structure-activity features in common between mammalian histidine decarboxylase and ornithine decarboxylase. Biochem J 320 (Pt 2): 365-368.
21. Penalti G, Law RH, Buckle AM, Langendorf C, Tuck K, Rosado CJ et al. (2007). GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct MoI Biol 14: 280-286. (Pubitemid 46608350)
22. Fiser A, Sali A (2003). Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374: 461-491. (Pubitemid 37531821)
23. Fitz LJ, Brennan A, Wood CR, Goldman SJ, Kasaian MT (2008). Activation-induced cellular accumulation of histamine in immature but not mature murine mast cells. Cell Mol Life Sci 65: 1585-1595.
24. Fleming JV, Fajardo I, Langlois MR, Sanchez-Jimenez F, Wang TC (2004a). The C-terminus of rat L-histidine decarboxylase specifically inhibits enzymic activity and disrupts pyridoxal phosphatedependent interactions with L-histidine substrate analogues. Biochem J 381 (Pt 3): 769-778. (Pubitemid 39120487)
25. Fleming JV, Sanchez-Jimenez F, Moya-Garcia AA, Langlois MR, Wang TC (2004b). Mapping of catalytically important residues in the rat L-histidine decarboxylase enzyme using bioinformatic and sitedirected mutagenesis approaches. Biochem J 379 (Pt 2): 253-261. (Pubitemid 38570097)
26. Furuta K, Nakayama K, Sugimoto Y, Ichikawa A, Tanaka S (2007). Activation of histidine decarboxylase through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815. J Biol Chem 282: 13438-13446. (Pubitemid 47100506)
27. Garcia-Viloca M, Gao J, Karplus M, Truhlař DG (2004). How enzymes work: analysis by modern rate theory and computer simulations. Science 303: 186-195. (Pubitemid 38057561)
28. Gil-Redondo R (2006). Master Thesis: Implementation de una plataforma para el cribado virtual de quimiotecas. UNED edn: Madrid.
29. Gil-Redondo R, Estrada J, Morreale A, Herranz F, Sancho J, Ortiz AR (2009). VSDMIP: virtual screening data management on an integrated platform. J Comput Aided Mol Des 23: 171-184.
30. van Gunsteren WF, Billeter SR, Eising AA, Hunenberger PH, Krüger P, Mark AE etal. (1996). Biomolecular Simulation: The GROMOS96 Manual and User Guide. Vdf Hochschulverlag: Zürich.
31. Gurevich VV, Gurevich EV (2008). Rich tapestry of G protein-coupled receptor signaling and regulatory mechanisms. Mol Pharmacol 74: 312-316.
32. Haas HL, Sergeeva OA, Selbach O (2008). Histamine in the nervous system. Physiol Rev 88: 1183-1241.
33. Haavik J, Blau N, Thony B (2008). Mutations in human monoaminerelated neurotransmitter pathway genes. Hum Mutat 29: 891-902. (Pubitemid 351951283)
34. Hansson T, Oostenbrink C, van Gunsteren W (2002). Molecular dynamics simulations. Curr Opin Struct Biol 12: 190-196.
35. Hillisch A, Pineda LF, Hilgenfeld R (2004). Utility of homology models in the drug discovery process. Drug Discov Today 9: 659-669. (Pubitemid 38981720)
36. Huang N, Shoichet BK, Irwin JJ (2006). Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801.
37. Irwin JJ, Shoichet BK (2005). ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.
38. Jacobson M, Sali A (2004). Comparative protein structure modeling and its applications to drug discovery. Annu Rep Med Chem 39: 259-276. (Pubitemid 39752327)
39. John B, Sali A (2003). Comparative protein structure modeling by iterative alignment, model building and model assessment. Nucleic Acids Res 31: 3982-3992. (Pubitemid 37442277)
40. Jorgensen EA, Knigge U, Warberg J, Kjaer A (2007). Histamine and the regulation of body weight. Neuroendocrinology 86: 210-214.
41. Kortagere S, Chekmarev D, Welsh WJ, Ekins S (2008). New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res 25: 1836-1845.
42. Kuntz ID, Blaney JM, Oatley SJ, Landridge R, Ferrin TE (1982). A geometric approach to macromolecule - ligand interactions. J Mol Biol 161: 269-288.
43. Kuramasu A, Sukegawa J, Yanagisawa T, Yanai K (2006). Recent advances in molecular pharmacology of the histamine systems: roles of C-terminal tails of histamine receptors. J Pharmacol Sci 101: 7-11. (Pubitemid 43765330)
44. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26. (Pubitemid 33653411)
45. Malakoutikhah M, Teixido M, Giralt E (2008). Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries. J Med Chem 51: 4881-4889.
46. Marti S, Roca M, Andres J, Moliner V, Silla E, Tunon I etal. (2004). Theoretical insights In enzyme catalysis. Chem Soc Rev 33: 98-107.
47. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, MeIo F, Sali A (2000). Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325. (Pubitemid 30599596)
48. Massova I, Kollman PA (2000). Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des 200: 113-135. (Pubitemid 30191024)
49. Medina MA, Urdíales JL, Rodriguez-Caso C, Ramirez FJ, SanchezJimenez F (2003). Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications. Crit Rev Biochem MoI Biol 38: 23-59. (Pubitemid 36308350)
50. Medina MA, Correa-Fiz F, Rodriguez-Caso C, Sanchez-Jimenez F (2005). A comprehensive view of polyamine and histamine metabolism to the light of new technologies. J Cell MoI Med 9: 854-864. (Pubitemid 43116551)
51. Melgarejo E, Medina MA, Sanchez-Jimenez F, Botana LM, Domínguez M, Escribano L etal. (2007). Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes. Cell Mol Life Sd 64: 2690-2701.
52. Morreale A, Gil-Redondo R, Ortiz AR (2007). A new implicit solvent model for protein-ligand docking. Proteins 67: 606-616. (Pubitemid 46625577)
53. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK et al. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662. (Pubitemid 128590223)
54. Moya-Garcia AA, Medina MA, Sanchez-Jimenez F (2005). Mammalian histidine decarboxylase: from structure to function. Bioessays 27: 57-63. (Pubitemid 40128623)
55. Moya-Garcia AA, Pino-Angeles A, Sanchez-Jimenez F (2006). New structural insights to help in the search for selective Inhibitors of mammalian pyridoxal 5'-phosphate-dependent histidine decarboxylase. 4. Synthesis, metabolism and release of histamine. Inflamm Res 55 (Suppl. 1): S55-S56. (Pubitemid 43760591)
56. Moya-Garcia AA, Ruiz-Pernia J, Marti S, Sanchez-Jimenez F, Tunon I (2008). Analysis of the decarboxylation step in mammalian histidine decarboxylase. A computational study. J Biol Chem 283: 12393-12401.
57. Mulholland AJ (2005). Modelling enzyme reaction mechanisms, specificity and catalysis. Drug Discov Today 10: 1393-1402. (Pubitemid 41501794)
58. Neider JA, Mead R (1965). A simplex method for function minimization. Comput J 7: 308-313.
59. Nitta Y, Kikuzaki H, Ueno H (2007). Food components inhibiting recombinant human histidine decarboxylase activity. J Agrie Food Chem 55: 299-304. (Pubitemid 46586310)
60. Norberg J, Nilsson L (2003). Advances in biomolecular simulations: methodology and recent applications. Q Rev Biophys 36: 257-306. (Pubitemid 38268659)
61. Ohtsu H (2008). Progress in allergy signal research on mast cells: the role of histamine in immunological and cardiovascular disease and the transporting system of histamine in the cell. J Pharmacol Set 106: 347-353.
62. Olmo MT, Rodriguez-Agudo D, Medina MA, Sanchez-Jimenez F (1999). The pest regions containing C-termini of mammalian ornithine decarboxylase and histidine decarboxylase play different roles in protein degradation. Biochem Biophys Res Commun 257: 269-272. (Pubitemid 29301433)
63. Olmo MT, Urdíales JL, Pegg AE, Medina MA, Sanchez-Jimenez F (2000). In vitro study of proteolytic degradation of rat histidine decarboxylase. Eur J Biochem 267: 1527-1531. (Pubitemid 30143293)
64. Olmo MT, Sanchez-Jimenez F, Medina MA, Hayashi H (2002). analysis of recombinant rat histidine decarboxylase. J Biochem 132: 433-439.
65. Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS (2002). Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 46: 34-40. (Pubitemid 34033574)
66. Perez C, Ortiz AR (2001). Evaluation of docking functions for protein-ligand docking. J Med Chem 44: 3768-3785.
67. Rana K, Peters MB, Wang B, Yu N, Wollacott AM, Westerhoff LM et al. (2007). The role of quantum mechanics in structure-based drug design. Drug Discov Today 12: 725-731.
68. Ridder L, Harvey JN, Rietjens IMCM, Vervoort J, Mulholland AJ (2003). Ab initio qm/mm modeling of the hydroxylation step in p-hydroxybenzoate hydroxylase. J Phys Chem B 107: 2118-2126.
69. Rodriguez-Agudo D, Olmo MT, Sanchez-Jimenez F, Medina MA (2000). Rat histidine decarboxylase is a substrate for m-calpain in vitro. Biochem Biophys Res Commun 271: 777-781. (Pubitemid 30444704)
70. Rodriguez-Caso C, Rodriguez-Agudo D, Moya-Garcia AA, Fajardo I, Medina MA, Subramaniam V et al. (2003a). Local changes in the catalytic site of mammalian histidine decarboxylase can affect its global conformation and stability. Eur j Biochem 270: 4376-4387. (Pubitemid 37340356)
71. Rodriguez-Caso C, Rodriguez-Agudo D, Sanchez-Jimenez F, Medina MA (2003b). Green tea epigallocatechin-3-gallate is an inhibitor of mammalian histidine decarboxylase. Cell Mol Life Sci 60: 1760-1763. (Pubitemid 37041372)
72. Sander C, Schneider R (1991). Database of homology-derived proteinstructures and the structural meaning of sequence alignment. Proteins 9: 56-68.
73. Sandmeier E, Hale TI, Christen P (1994). Multiple evolutionary origin of pyridoxal-5'-phosphate-dependent amino acid decarboxylases. Eur J Biochem 221: 997-1002. (Pubitemid 24146200)
74. Schubert ML, Peura DA (2008). Control of gastric acid secretion in health and disease. Gastroenterology 134: 1842-1860.
75. Shoichet BK (2004). Virtual screening of chemical libraries. Nature 432: 862-865.
76. Smith A (2002). Screening for drug discovery: the leading question.Nature 418: 453-459. (Pubitemid 34826849)
77. Snow CD, Sorin EJ, Rhee YM, Pande VS (2005). How well can simulation predict protein folding kinetics and thermodynamics? Annu Rev Biophys Biomol Struct 34: 43-69.
78. Sorensen TL, McAuley KE, Flaig R, Duke EM (2006). New light forscience: synchrotron radiation in structural medicine. Trends Biotechnol 24: 500-508. (Pubitemid 44537458)
79. Sousa SF, Fernandes PA, Ramos MJ (2006). Protein-ligand docking: current status and future challenges. Proteins 65: 15-26. (Pubitemid 44320611)
80. Sun H (2008). Pharmacophore-based virtual screening. Curr Med Chem 15: 1018-1024.
81. Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T etal. (2008). Activation of peroxisome proliferatoractivated receptor gamma suppresses mast cell maturation involved in allergic diseases. Allergy 63: 1136-1147.
82. Tanaka S, Ichikawa A (2006). Recent advances in molecular pharmacology of the histamine systems: immune regulatory roles of histamine produced by leukocytes. J Pharmacol Sci 101: 19-23. (Pubitemid 43765332)
83. Thurmond RL, GeIfand EW, Dunford PJ (2008). The role of histamine Hl and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 7: 41-53.
84. Totrov M, Abagyan R (2008). Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18: 178-184.
85. Tramontano A, Morea V (2003). Exploiting evolutionary relationships for predicting protein structures. Biotechnol Bioeng 84: 756762. (Pubitemid 38089691)
86. Viguera E, Trelles O, Urdíales JL, Matés JM, Sánchez-Jiménez F (1994). Mammalian L-amino acid decarboxylases producing 1,4-diamines: analogies among differences. Trends Biochem Sci 19: 318-319. (Pubitemid 24259982)
87. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH etal. (2006). A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931.
88. Warshel A (2003). Computer simulations of enzyme catalysis: methods, progress, and insights. Annu Rev Biophys Blomol Struct 32: 425-443.
89. Weininger D (1988). SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Model 28: 31-36.
90. Wijtmans M, Celanire S, Snip E, Gillard MR, Gelens E, Collart PP et al. (2008). 4-benzyl-lH-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem 51: 2944-2953. (Pubitemid 351706023)
91. Wu F, Yu J, Gehring H (2008). Inhibitory and structural studies of novel coenzyme-substrate analogs of human histidine decarboxylase. FASEB J 22: 890-897. (Pubitemid 351348140)
92. Xiang Z (2006). Advances in homology protein structure modeling. Curr Protein Pept Sci 7: 217-227. (Pubitemid 43881004)
93. Xie W, Song L, Truhlař DG, Gao J (2008). The variational explicit polarization potential and analytical first derivative of energy: towards a next generation force field. J Chem Phys 128: 234108.
94. Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR et al. (2008). The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem 51: 5423-5430.